JNTX-102

Generic Name: JNTX-102

Clinical Trials

To Study The Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction in Decompensated Cirrhotics Undergoing Less Than 5 Litres Of Ascitic Fluid Tap With Or Without Albumin Infusion.

Not Applicable

Completed

Conditions: Decompensated Cirrhosis

Interventions: Drug: Albumin
Drug: ascitic fluid

First Posted Date: 2015-06-10

Last Posted Date: 2017-06-12

Lead Sponsor: Institute of Liver and Biliary Sciences, India

Target Recruit Count: 80

Registration Number: NCT02467322

Locations: 🇮🇳
Institute of Liver and Biliary Sciences, New Delhi, Delhi, India

Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction In Acute-On-Chronic Liver Failure.

Not Applicable

Completed

Conditions: Acute on Chronic Liver Failure

Interventions: Drug: Albumin
Drug: Ascitic fluid

First Posted Date: 2015-06-10

Last Posted Date: 2017-11-28

Lead Sponsor: Institute of Liver and Biliary Sciences, India

Target Recruit Count: 80

Registration Number: NCT02467348

Locations: 🇮🇳
Institute of Liver and Biliary Sciences, New Delhi, Delhi, India

Efficacy of IntraVenous ImmunoGlobulins in Toxic Shock Syndromes: a Paediatric Pilot Study

Phase 2

Completed

Conditions: Toxic Shock Syndrome

Interventions: Drug: Albumin
Drug: Intravenous human immunoglobulin

First Posted Date: 2014-08-18

Last Posted Date: 2021-06-08

Lead Sponsor: Hospices Civils de Lyon

Target Recruit Count: 30

Registration Number: NCT02219165

Locations: 🇫🇷
Hôpital Femme Mère Enfant, Bron, France

The INFECIR-2 Albumin Prevention Study

Phase 4

Terminated

Conditions: Advanced Chronic Liver Disease
Urinary Infection
Pneumonia
Cholangitis
Other Bacterial Diseases

Interventions: Drug: Albumin

First Posted Date: 2014-01-13

Last Posted Date: 2017-05-18

Lead Sponsor: EASL - CLIF Consortium

Target Recruit Count: 136

Registration Number: NCT02034279

Locations: 🇪🇸
Hospital Clinic, Barcelona, Spain

Comparison of Hemodynamic Effects of Two Colloid Therapies in Post-operative Patients Undergoing Pancreaticoduodenectomy

Phase 3

Completed

Conditions: Pancreaticoduodenectomy

Interventions: Drug: Albumin
Drug: 6% hydroxyethyl starch 130/0.4

First Posted Date: 2013-01-01

Last Posted Date: 2013-01-03

Lead Sponsor: Asan Medical Center

Target Recruit Count: 100

Registration Number: NCT01758172

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure

Phase 2

Withdrawn

Conditions: Fibrosis
Renal Failure
Hepatorenal Syndrome

Interventions: Drug: Albumin
Drug: Midodrine
Drug: Octreotide

First Posted Date: 2012-04-30

Last Posted Date: 2019-02-15

Lead Sponsor: Anna Cruceta

Registration Number: NCT01587222

Locations: 🇪🇸
Hospital Clinic i Provincial de Barcelona, Barcelona, Spain

Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy

Phase 4

Completed

Conditions: Hepatic Encephalopathy

Interventions: Drug: Albumin

First Posted Date: 2012-03-21

Last Posted Date: 2013-12-17

Lead Sponsor: University of Roma La Sapienza

Target Recruit Count: 20

Registration Number: NCT01559519

Lactated Ringer Versus Albumin in Early Sepsis Therapy

Phase 3

Completed

Conditions: Septic Shock
Severe Sepsis

Interventions: Drug: Albumin
Drug: Lactated Ringer

First Posted Date: 2011-04-19

Last Posted Date: 2018-04-05

Lead Sponsor: University of Sao Paulo

Target Recruit Count: 360

Registration Number: NCT01337934

Locations: 🇧🇷
Cancer Institute of Sao Paulo, School of Medicine, University of Sao Paulo, Sao Paulo, Sao Paulo/SP, Brazil

Albumin for Intracerebral Hemorrhage Intervention

Phase 2

Terminated

Conditions: Intracerebral Hemorrhage

Interventions: Drug: Placebo
Drug: Albumin
Procedure: Brain MRI with and without contrast

First Posted Date: 2009-10-07

Last Posted Date: 2014-08-29

Lead Sponsor: Georgetown University

Target Recruit Count: 14

Registration Number: NCT00990509

Locations: 🇺🇸
Georgetown University Hospital, Washington, District of Columbia, United States

Effects of Long Term Albumin 20% Administration in Patients With Cirrhosis and Ascites.

Phase 4

Completed

Conditions: Cirrhosis
Ascites

Interventions: Drug: Albumin

First Posted Date: 2009-08-31

Last Posted Date: 2019-06-26

Lead Sponsor: Instituto Grifols, S.A.

Target Recruit Count: 33

Registration Number: NCT00968695

Locations: 🇪🇸
Hospital del Mar, Barcelona, Spain
🇪🇸
Hospital Universitario Ramón y Cajal, Madrid, Spain
🇪🇸
Hospital Clínic of Barcelona, Barcelona, Spain

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy